By Professor Richard Bryan Lock

Journal articles

de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF, 2019, 'T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development', Haematologica, 104, pp. e204 - e207, http://dx.doi.org/10.3324/haematol.2018.198424

Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua G-A; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS, 2019, 'Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.', Haematologica, 104, pp. e300 - e303, http://dx.doi.org/10.3324/haematol.2018.192906

Evans K; Duan JX; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB, 2019, 'OBI-3424, a novel AKR1c3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL', Clinical Cancer Research, 25, pp. 4493 - 4503, http://dx.doi.org/10.1158/1078-0432.CCR-19-0551

Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ; Bongers A, 2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, 146, pp. 1902 - 1916, http://dx.doi.org/10.1002/ijc.32582

Bayat N; McOrist N; Ariotti N; Lai M; Sia KCS; Li Y; Grace JL; Quinn JF; Whittaker MR; Kavallaris M; Davis TP; Lock RB, 2019, 'Thiol-reactive star polymers functionalized with short ethoxy-containing moieties exhibit enhanced uptake in acute lymphoblastic leukemia cells', International Journal of Nanomedicine, 14, pp. 9795 - 9808, http://dx.doi.org/10.2147/IJN.S220326

Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB, 2018, 'Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia', Cancer Cell, 34, pp. 906 - 921.e8, http://dx.doi.org/10.1016/j.ccell.2018.11.002

Wakefield CE; Doolan EL; Fardell JE; Signorelli C; Quinn VF; Tucker KM; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, 'The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care', EBioMedicine, 37, pp. 205 - 213, http://dx.doi.org/10.1016/j.ebiom.2018.10.060

Wakefield CE; Doolan EL; Fardell JE; Signorelli C; Quinn VF; Tucker KF; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, 'Protocol for the avatar acceptability study: A multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand', BMJ Open, 8, pp. e024064, http://dx.doi.org/10.1136/bmjopen-2018-024064

McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL, 2018, 'Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression', British Journal of Cancer, 118, pp. 1000 - 1004, http://dx.doi.org/10.1038/s41416-018-0022-0

Jones L; Richmond J; Evans K; Carol H; Jing D; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB, 2017, 'Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL', Clinical Cancer Research, 23, pp. 3744 - 3755, http://dx.doi.org/10.1158/1078-0432.CCR-16-2392

Brumatti G; Ma C; Lalaoui N; Nguyen N-Y; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J, 2017, 'The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia (vol 8, 339ra69, 2016)', SCIENCE TRANSLATIONAL MEDICINE, 9, http://dx.doi.org/10.1126/scitranslmed.aan8181

Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2017, 'Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 64, pp. e26263, http://dx.doi.org/10.1002/pbc.26263

Kurmasheva RT; Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Kang M; Reynolds CP; Wu J; Houghton PJ; Smith MA, 2017, 'Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 64, pp. e26304, http://dx.doi.org/10.1002/pbc.26304

Jones L; Carol H; Evans K; Richmond J; Houghton PJ; Smith MA; Lock RB, 2016, 'A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program', Leukemia, 30, pp. 2133 - 2141, http://dx.doi.org/10.1038/leu.2016.192

Murphy B; Yin H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Kurmasheva RT; Dvorchik I; Wu J; Billups CA; Boateng N; Smith MA; Lock RB; Houghton PJ, 2016, 'Evaluation of alternative in vivo drug screening methodology: A single mouse analysis', Cancer Research, 76, pp. 5798 - 5809, http://dx.doi.org/10.1158/0008-5472.CAN-16-0122

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 63, pp. 1744 - 1752, http://dx.doi.org/10.1002/pbc.26064

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006))', Cancer Cell, 30, pp. 499 - 500, http://dx.doi.org/10.1016/j.ccell.2016.08.009

Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DCS; Lock RB, 2016, 'Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia', Blood, 128, pp. 1382 - 1395, http://dx.doi.org/10.1182/blood-2016-03-707414

Trahair TN; Lock RB; Sutton R; Sia KCS; Evans K; Richmond J; Law T; Venn NC; Irving JA; Moore S; Nievergall E; Dang P; Heatley SL; White DL; Revesz T, 2016, 'Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL', Bone Marrow Transplantation, 51, pp. 1279 - 1282, http://dx.doi.org/10.1038/bmt.2016.122

Richmond J; Robbins A; Evans K; Beck D; Kurmasheva RT; Billups CA; Carol H; Heatley S; Sutton R; Marshall GM; White D; Pimanda J; Houghton PJ; Smith MA; Lock RB, 2016, 'Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant', Cancer Research, 76, pp. 4579 - 4591, http://dx.doi.org/10.1158/0008-5472.CAN-16-0523

Huang Y; Thoms JAI; Tursky ML; Knezevic K; Beck D; Chandrakanthan V; Suryani S; Olivier J; Boulton A; Glaros EN; Thomas SR; Lock RB; MacKenzie KL; Bushweller JH; Wong JWH; Pimanda JE, 2016, 'MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation', Leukemia, 30, pp. 1552 - 1561, http://dx.doi.org/10.1038/leu.2016.55

Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; De Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J, 2016, 'The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia', Science Translational Medicine, 8, http://dx.doi.org/10.1126/scitranslmed.aad3099

Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T, 2016, 'The bromodomain inhibitor jq1 and the histone deacetylase inhibitor panobinostat synergistically reduce n-myc expression and induce anticancer effects', Clinical Cancer Research, 22, pp. 2534 - 2544, http://dx.doi.org/10.1158/1078-0432.CCR-15-1666

Dolai S; Sia KCS; Robbins AK; Zhong L; Heatley SL; Vincent TL; Hochgräfe F; Sutton R; Kurmasheva RT; Revesz T; White DL; Houghton PJ; Smith MA; Teachey DT; Daly RJ; Raftery MJ; Lock RB, 2016, 'Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia', Cancer Research, 76, pp. 2766 - 2777, http://dx.doi.org/10.1158/0008-5472.CAN-15-2786

Churchman ML; Evans K; Richmond J; Robbins A; Jones L; Shapiro IM; Pachter JA; Weaver DT; Houghton PJ; Smith MA; Lock RB; Mullighan CG, 2016, 'Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL', JCI Insight, 1, pp. e86082, http://dx.doi.org/10.1172/jci.insight.86082

Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Reynolds CP; Kang MH; Billups CA; Collins J; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 63, pp. 443 - 450, http://dx.doi.org/10.1002/pbc.25826

Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW, 2016, 'The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid Leukemia', Cancer Research, 76, pp. 1158 - 1169, http://dx.doi.org/10.1158/0008-5472.CAN-15-1070

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics', Cancer Cell, 29, pp. 145 - 158, http://dx.doi.org/10.1016/j.ccell.2016.01.006

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

El-Hoss J; Jing D; Evans K; Toscan C; Xie J; Lee H; Taylor RA; Lawrence MG; Risbridger GP; MacKenzie KL; Sutton R; Lock RB, 2016, 'A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts', Oncotarget, 7, pp. 60475 - 60490, http://dx.doi.org/10.18632/oncotarget.11125

Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM, 2016, 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7, pp. 47465 - 47478, http://dx.doi.org/10.18632/oncotarget.10167

Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB, 2016, 'Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia', Oncotarget, 7, pp. 58728 - 58742, http://dx.doi.org/10.18632/oncotarget.11233

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, http://dx.doi.org/10.1002/pbc.26064

Manesh DM; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB, 2015, 'AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia', Blood, 126, pp. 1193 - 1202, http://dx.doi.org/10.1182/blood-2014-12-618900

Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; We A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB, 2015, 'Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice', Haematologica, 100, pp. 914 - 926, http://dx.doi.org/10.3324/haematol.2014.113092

Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB, 2015, 'Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts', Organic and Biomolecular Chemistry, 13, pp. 6299 - 6312, http://dx.doi.org/10.1039/c5ob00779h

Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 62, pp. 1106 - 1109, http://dx.doi.org/10.1002/pbc.25329

Tursky ML; Beck D; Thoms JAI; Huang Y; Kumari A; Unnikrishnan A; Knezevic K; Evans K; Richards LA; Lee E; Morris J; Goldberg L; Izraeli S; Wong JWH; Olivier J; Lock RB; MacKenzie KL; Pimanda JE, 2015, 'Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias', Leukemia, 29, pp. 819 - 827, http://dx.doi.org/10.1038/leu.2014.299

Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB, 2015, 'Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia', Clinical Cancer Research, 21, pp. 1395 - 1405, http://dx.doi.org/10.1158/1078-0432.CCR-14-2300

Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ, 2015, 'Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program', Clinical Cancer Research, 21, pp. 819 - 832, http://dx.doi.org/10.1158/1078-0432.CCR-14-2572

Dolai S; Lock R, 2015, 'Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia', Blood, 125, pp. 1759 - 1767, http://dx.doi.org/10.1182/blood-2014-06-580480

Suryani S; Bracken LS; Harvey RC; Sia KCS; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB, 2015, 'Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia', Molecular Cancer Therapeutics, 14, pp. 364 - 374, http://dx.doi.org/10.1158/1535-7163.MCT-14-0647

Goossens S; Radaelli E; Blanchet O; Durinck K; Van Der Meulen J; Peirs S; Taghon T; Tremblay CS; Costa M; Ghahremani MF; De Medts J; Bartunkova S; Haigh K; Schwab C; Farla N; Pieters T; Matthijssens F; Van Roy N; Best JA; Deswarte K; Bogaert P; Carmichael C; Rickard A; Suryani S; Bracken LS; Alserihi R; Canté-Barrett K; Haenebalcke L; Clappier E; Rondou P; Slowicka K; Huylebroeck D; Goldrath AW; Janzen V; McCormack MP; Lock RB; Curtis DJ; Harrison C; Berx G; Speleman F; Meijerink JPP; Soulier J; Van Vlierberghe P; Haigh JJ, 2015, 'ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling', Nature Communications, 6, pp. 5794, http://dx.doi.org/10.1038/ncomms6794

Carol H; Fan MMY; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB, 2015, 'Efficacy of CPX-351, (cytarabine: DAunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 62, pp. 65 - 71, http://dx.doi.org/10.1002/pbc.25133

Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ, 2015, 'Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673', Pediatric Blood and Cancer, 62, pp. 91 - 98, http://dx.doi.org/10.1002/pbc.25201

Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB, 2015, 'P21^WAF1 modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia', Cell Cycle, 14, pp. 3602 - 3612, http://dx.doi.org/10.1080/15384101.2015.1100774

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

Nowak D; Liem NLM; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP, 2015, 'Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance', Experimental Hematology, 43, pp. 32 - 43, http://dx.doi.org/10.1016/j.exphem.2014.09.007

Jing RBAB; Thoms J; Pimanda J; Wong J; Beck D; Lock R; Knezevic K; Jing D; Bhadri V; Yakob N, 2015, 'Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells', Blood, 125, pp. 273 - 283, http://dx.doi.org/10.1182/blood-2014-05-576470

Toscan CE; Failes T; Arndt GM; Lock RB; Arndt G, 2014, 'High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers', Journal of Biomolecular Screening, 19, pp. 1391 - 1401, http://dx.doi.org/10.1177/1087057114546550

Back to profile page